News from Alnylam® Pharmaceuticals | Canada

Car driving on road from above

NEWS FROM ALNYLAM

Here you can find the latest press releases from Alnylam.

Download PDF ›193.57 KB

PRESS RELEASE
March 17, 2021

Alnylam Wins Prestigious Prix Galien Canada Award for Best Innovative Product with First-Ever Health Canada-Approved RNAi Therapeutic, ONPATTRO® (patisiran)193.57 KB

Download PDF ›80.48 KB

PRESS RELEASE
July 23, 2019

Alnylam launches the first ever RNAi therapeutic approved in Canada80.48 KB

Download PDF ›1.29 MB

PRESS RELEASE
May 15, 2019

Harnessing RNAi: Alnylam Pharmaceuticals is conquering rare diseases one drug at a time1.29 MB

Download PDF ›269.41 KB

PRESS RELEASE
November 26, 2018

Alnylam Pharmaceuticals: Bringing groundbreaking gene silencing therapies to Ontario.269.41 KB

Download PDF ›95.3 KB

PRESS RELEASE
September 24, 2018

Alnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy95.3 KB

GET IN TOUCH

Questions, concerns, or comments about this content? We encourage you to reach out to our team.

OTHER INQUIRIES

Media: media@alnylam.com

Investor Relations: investors@alnylam.com

General: info@alnylam.ca